Shots:

• The CHMP positive opinion is based on P-III CASSIOPEIA (MMY3006) study assessing the combination of Darzalex + bortezomib- thalidomide and dexamethasone vs bortezomib- thalidomide and dexamethasone alone in 1-085 newly diagnosed patients with previously untreated symptomatic MM- eligible for ASCT
• If approved- the combination regimen will be the first Darzalex based regimen that would be a potential treatment option for newly diagnosed patients with MM who are eligible for ASCT in the EU
• Darzalex is a CD38-directed antibody and is an approved therapy as monothx. or in combination with other drugs in multiple countries including the US for MM. In Aug’2012- Genmab granted exclusive rights of Darzalex to Janssen

Click here to­ read full press release/ article

 Ref: GlobeNewswire | Image: Janssen